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During the four years, 1980 to 1983, 83 Minnesota residents have been diagnlosed with Lyme
disease. Sixty-five of the patients were male. The median age of patients was 39 years with a
range from one to 77 years. Seventy-five (90 percent) had onset in 1982 and 1983. Of these lat-
ter cases, 56 (75 percent) recalled a tick bite three to 27 days prior to the development of
erythema chronicum migrans. Patients experienced possible exposure to Ixodes dammini in at
least 24 (28 percent) of the 87 Minnesota counties; however, over 50 percent had reported ex-
posure in one ofeight east-central counties near or immediately west of the Wisconsin border.
Serologic studies for antibody against the Ixodesdammini spirochete were completed on 30 pa-
tients with onset in 1982 and 1983. Of 28 patients with paired acute and convalescent serum
samples, only two (7 percent) had fourfold rises in antibody titers. Lyme disease is an emerging
public health problem in Minnesota. Additional studies are needed to define the risk ofdisease
by geographic area within the state. Physicians statewide should be alert to the possibility of
Lyme disease among their patients, since only 39 percent of patients with onset in 1982 and
1983 were exposed in their county of residence.
Our understanding of the natural history of Lyme disease has progressed signifi-
cantly since its first recognition in 1975 and the first reports in the medical literature
by Steere et al. in 1977 [1,2]. Lyme disease, with typical onset during the summer
months, begins most often with the unique skin lesion, erythema chronicum migrans
(ECM). It may be accompanied by headache, stiff neck, fever, myalgias, arthral-
gias, malaise, fatigue, or lymphadenopathy [1,3]. Latter manifestations of the
disease may include arthritis, neuropathies, myocarditis or atrioventricular-node
block, migratory musculoskeletal pain, and meningoencephalitis [2,4-6].
Subsequent studies have shown that penicillin or tetracycline given early in the
illness have shortened the duration of ECM and attenuated or completely prevented
arthritis; that a spirochete transmitted by the newly identified tick Ixodes dammini,
or by related ixodid ticks, is the agent responsible for Lyme disease; and that by in-
direct immunofluorescence assay (IFA), human serologic responses to the spirochete
can be documented [3,7-11].
Patients with Lyme disease report confirmed or possible tick exposures in at least
14 states, Europe, and Australia [4,11-16]. Despite increasing interest in this newly
described disease, there is only limited data on incidence of it throughout the world
and, in particular, in many areas of the United States. We report here on the
epidemiologic and serologic findings of our studies of Lyme disease in Minnesota.
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Our surveillance effort for Lyme disease has primarily been an epidemiologically
defined passive system. That is, the Minnesota Department of Health (MDH) per-
sonnel did not routinely survey physicians in the state for case assessment. Since
1980, as part of our passive surveillance system, we have published an article re-
garding Lyme disease each spring in the MDH Disease Control Newsletter, a publi-
cation received by more than 6,000 state health professionals. Physicians and other
health professionals wereencouraged in these articles to report cases of Lyme disease
to local health agencies or the Acute Disease Epidemiology Section of the MDH. In
April 1982, we collaborated with three local physicians in the publication of an arti-
cle on Lyme disease in the state medical journal [12]. In the spring of 1983 we also
publicized, to the medical community, the availability through MDH of serologic
testing for patients with possible Lyme disease.
A patient was considered to have Lyme disease ifthere was presence of ECM and
a physician's diagnosis of Lyme disease; or if the patient did not experience ECM
but had systemic illness characteristicof Lyme disease and an indirect immuno-
fluorescence assay titer for Ixodes dammini spirochete greater than or equal to
1:256. Information regarding travel to a known endemic area for Lyme disease or a
history of tick bite was not required to fulfill the case criteria.
Reports of possible Lyme cases taken by telephone were noted on a standard
Lyme disease surveillance form; it included information on patient demographic
data, history ofexposure to ticks and tick bites, recent travel history, detailed clini-
cal and laboratory findings, and antibiotic treatment history. Following initial re-
ports, review ofthe available clinical and laboratory data was conducted. Interviews
ofpatients were conducted by the local health agency, MDH epidemiologists, or the
patient's physician. All clinical data were confirmed with the patient's physician.
Antibody titers against the Ixodes dammini spirochete were determined by indirect
immunofluorescence assay at the Centers for Disease Control (CDC) [17].
RESULTS
During the four years, 1980 to 1983, 83 Minnesota residents have been diagnosed
with Lyme disease(seeFig. 1). Seventy-five (90percent) had onset in 1982 and 1983.
Our results will specifically address these 75 patients. They had onset of illness be-
tween the months of March and October, with 69 percent of the onsets in June or
July(Fig. 2). Fifty-sixpatients (75 percent) recalled a tick bite three to 27 days prior
to the development of ECM. In particular, two cases, one with onset in late March
and the other with onset inmid-April, remember bites by a small and unusual "wood
tick" prior to illness. The description provided by the patients ofthe two biting ticks
supports the conclusion that they were Ixodes dammini.
Fifty-six (75 percent) of the patients were exposed within the state of Minnesota
(i.e., no travel history outside the state). Thirteen (17 percent) residents had ex-
posure in Wisconsin, one (1 percent) in Michigan, one (1 percent) in Georgia, and
four(5 percent) with probable exposure locations unknown (i.e., travel history out-
side of the state but no documented tick bite). Of the patients with exposure in the
state, 27 patients (37 percent of all 1982 and 1983 patients) had exposure within the
state but in a different county from their home residence and 29 (39 percent of all
1982 and 1983 patients) had exposure in the same county as their home residence.
Forty-nine (65 percent) of the 75 patients were male. The median age of patients
was 39 years, with arange from one to 77 years. The ages ofthe patients appear to
reflect the approximate age of Minnesota residents (Table 1).
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FIG. 1. Reported cases of Lymne disease by year, Minnie-
sota, 1979-1983.
Patients had tick bite exposures in at least 24 (28 percent) of the 87 Minnesota
counties (Fig. 3). In particular, over 50 percent ofthe cases reported exposure in one
of eight east-central counties, near or immediately west of the Wisconsin border.
However, some patients recorded exposure in counties as far as 150 miles from this
eight-county area.
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TABLE 1
Reported Patients with Lyme
Disease in Minnesota by Age,
1982 and 1983
Age (Years) Number (o)
s 19 16 (21)
20-39 24 (32)
40-59 21 (28)
.60 14 (19)
Total 75 (100)
Serologic studies were completed on 30 patients, eight with onset in 1982 and 22
with onset in 1983. Twenty patients (66 percent) had ECM only, eight patients (27
percent) had ECM and systemic illness (i.e., fever, arthralgias, myalgias), and two
patients (7 percent) had ECM with eventual cardiac or neuralgic complications.
Twenty-eight patients provided acute (1 to 14 days after onset of ECM) and con-
FIG. 3. Reported Lyme disease cases in Minnesota by county of exposure, 1982 and
1983.LYME DISEASE IN MINNESOTA
TABLE 2
Relationship Between Interval from Onset of Erythema
Chronicum Migrans to Appropriate Antibiotic Therapya and
Indirect Immunofluorescence Antibody (IFA) Titer for Ixodes
dammini Spirochete among Patients with Lyme Disease,
Minnesota, 1982 and 1983
Interval From Onset to Therapyb
< 10 Days > 10 Days or None
IFA Titer Number (o) Number (%)
2 1:256 2 (20) 8 (42)
< 1:256 8 (80) 11 (58)
Total 10 (100) 19 (100)
aAppropriate antibiotic therapy included use of penicillin and
tetracycline as outlined by Steere et al. [8].
bp = 0.18 (titer for c 10 days vs. titer for > 10 days).
valescent (30 to 60 days after onset ofECM) serum samples. One patient had a single
serum obtained 42 days after onset and a second patient had a single serum obtained
four days after onset. Of the 28 patients with paired samples, only two (7 percent)
had fourfold rises in antibody titers. Ofthe 29 patients with at least one serum sam-
ple obtained between 30 and 60 days after onset, 17 (59 percent) had an antibody
titer . 1:128 and only 10 (34 percent) had an antibody titer 2 1:256. Twenty-eight
of these 29 patients (97 percent) had ECM.
Two (20 percent) of 10 patients who received appropriate antibiotic therapy for
Lyme disease within ten days after onset of ECM had a convalescent titer . 1:256,
while eight (42 percent) of 19 patients who did not receive appropriate therapy
within ten days had a convalescent titer . 1:256 (p = 0.18) (Table 2).
DISCUSSION
Lyme disease is emerging as a new public health problem in Minnesota, as it is
elsewhere in the country. We have documented a ninefold increase in reported cases
for 1982 and 1983 when compared to the two previous years. This raises an im-
portant question of whether this increase reflects a rapidly growing number of cases
or is the result of an increased awareness and reporting of the disease by the Minne-
sota medical community. Our surveillance efforts to date for Lyme disease would be
classified as passive, although there was an effort in 1982 and 1983 to heighten
physician awareness of the disease and to report cases to the MDH. The impact of
different intensities and types of surveillance efforts on disease reporting has been
shown [18-23]. In particular, there can be a significant increase in case reports for a
disease that suddenly gains national importance and whose natural history is initially
unclear [22,23]. However, it is possible that there has been a significant increase in
the number or range of the Ixodes tick in Minnesota. It is also possible to speculate
that the Ixodes dammini spirochete has only recently become prevalent among the
Ixodes ticks in the state. Last, a less likely possibility, is that Minnesota residents are
now participating in more outdoor activities and therefore coming into contact with
the ticks more often than in the past.
Although a marked increase in the incidence of Lyme disease may have recently
occurred, without a regional or possibly even a statewide extensive retrospective
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medical chart review for patient diagnoses suggestive ofLyme disease, we will not be
able to comment further on the reason(s) for this increase. Regardless of reason(s),
Lyme disease is now an important public health problem in the state.
Of particular importance is the finding that only 75 percent of our patients had
their tick exposures in Minnesota and that only 37 percent had their exposures in the
same county as their home residence. This has important implications with respect
to the timely and accurate diagnosis of Lyme disease patients and the need to de-
termine the location of a tick exposure rather than the location of a patient's resi-
dence for the purposes ofepidemiologic study. With at least 14 states now reporting
cases of Lyme disease, it is possible to be bitten by an Ixodes tick whiletraveling and
subsequently develop illness days and miles from the geographic location of the ex-
posure. If physicians in the non-endemic areas do not obtain sufficient travel his-
tories from these patients or are not familiar with the clinical presentation of the
disease, it is unlikely that appropriate antibiotic therapy will be administered in a
timely manner. It is important that federal, state, and local public health agencies
make an effort to define those regions of the country with endemic Lyme disease
and those regions where a person could possibly be exposed to an infected Ixodes
tick. This information should be made known to practitioners nationwide.
One finding of our surveillance effort that differs from the experience by Steere et
al. is the gender and age distribution of patients. While 49 (65 percent) of 75 Min-
nesota patients are male, only 164 (52 percent) of 314 patients seen at Yale are male
(risk ratio = 1.7, p = 0.04) [3]. Also, the median age of Minnesota patients is 39
years, while those seen at Yale is 28 years. One possible explanation for this ap-
parent difference is the difference in the completeness of case reporting in Minne-
sota compared to the studies in the New England states.
The CDC has suggested that a titer of 1:256 or greater to the Ixodes dammini
spirochete in apatient with ongoing systemic illness is supportive ofthe diagnosis of
Lyme disease. They also indicate that similar serologic findings may not be helpful
in patients with only ECM. In our studies, of the 29 patients with uncomplicated
Lyme disease who had a serum sample obtained between 30 and 60 days after onset
ofECM, only 10(34 percent) had an antibody titer > 1:256. Also, ofthe 28 patients
with paired serum samples, only two (7 percent) had fourfold rises in antibody titers.
While there was some suggestion in our study that receiving appropriate antibiotic
therapy for Lyme disease within ten days after onset of ECM would abort an anti-
body response, only 42 percent of patients with more than ten days from onset of
ECM to therapy or no inappropriate therapy, had a titer > 1:256.
For the patient without recognizable ECM and not living in, or exposed to, a
known endemic area, the diagnosis ofLyme disease may be difficult. In particular, a
history of tick bite, or the lack of it, may be misleading because patients with Lyme
disease do not always remember a tick bite, and such bites are common in endemic
areas. A sensitive, specific, and standardized serologic test to assist in the diagnosis
ofLyme disease is clearly needed. Perhaps a single serum tested for the presence of a
specific IgM antibody against the Ixodes dammini spirochete will provide such a
test. Steere and colleagues found that, among 40 patients who had only ECM, 90
percent had IgM specific antibody between the ECM phase and convalescence [10].
Until a sensitive and specific serologic assay is available, Lyme disease
epidemiologic surveillance and studies in areas with sporadic cases, or on the border
of endemic areas, will be difficult. Such studies are necessary to define the incidence
of Lyme disease and, more specifically, to assist thephysician in regions ofthe coun-
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try not yet known to have the infected Ixodes ticks, in appropriately diagnosing and
treating these patients.
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